Coherus Oncology Inc.

Last updated September 27, 2026

Organization details

Legal name
Coherus Oncology Inc.
Former names
Coherus BioSciences, Inc. BioGenerics, Inc.
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
Redwood City
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
CHRS
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001512762
EIN
27-3615821
Wikidata ID
Q30268854

Board of directors

Chief executives

Dennis M. Lanfear · President & CEO
Dates unknown

Director election results

Annual meeting of June 11, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

6 of this board's directors also sit on 6 other boards. 6 are in the same sector.

Network of Coherus Oncology Inc.'s board connections Starling Oncology Inc. Starling Oncology Inc. BridgeBio Pharma Inc. BridgeBio Pharma Inc. Keros Therapeutics Inc. Keros Therapeutics Inc... Myriad Genetics Inc. Myriad Genetics Inc. Novavax Inc. Novavax Inc. TriSalus Life Sciences Inc. TriSalus Life Sciences... Ali J. Satvat Ali J. Satvat Charles W. Newton Charles W. Newton Kimberly Jo Tzoumakas Kimberly Jo Tzoumaka... Lee Nisley Newcomer Lee Nisley Newcomer Mark Stolper Mark Stolper Mats Wahlstrom Mats Wahlstrom Coherus Oncology Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Jun 5, 2026 Ali J. Satvat Director Grant or award +30,000 — —
Jun 5, 2026 Rita A. Karachun Director Grant or award +30,000 — —
Jun 5, 2026 Lee Nisley Newcomer Director Grant or award +30,000 — —
Jun 5, 2026 Michael Lee Ryan Director Grant or award +30,000 — —
Jun 5, 2026 Jill O'Donnell-Tormey Director Grant or award +30,000 — —
Jun 5, 2026 Mats Wahlstrom Director Grant or award +30,000 — —
Jun 5, 2026 Charles W. Newton Director Grant or award +30,000 — —
Jan 23, 2026 Dennis M. Lanfear Director, Officer (President & CEO) Grant or award +375,000 — —
Jan 22, 2026 McMichael Bryan J Officer (Chief Financial Officer) Grant or award +112,500 — —
Jan 20, 2026 McMichael Bryan J Officer (Chief Financial Officer) Shares withheld for tax −1,715 $1.55 $2,658
Jan 20, 2026 Dennis M. Lanfear Director, Officer (President & CEO) Shares withheld for tax −11,839 $1.55 $18,350
May 23, 2025 Mats Wahlstrom Director Open-market sale −99,988 $0.74 $73,991
Jan 20, 2025 McMichael Bryan J Officer (Chief Financial Officer) Shares withheld for tax −1,711 $1.39 $2,378
Jan 20, 2025 Reider Paul Officer (Chief Commercial Officer) Shares withheld for tax −4,858 $1.39 $6,753
Jan 20, 2025 Dennis M. Lanfear Director, Officer (President & CEO) Shares withheld for tax −11,810 $1.39 $16,416

Organizations in the same sector, closest in location and size first.

Questions about Coherus Oncology Inc.

Who is the CEO of Coherus Oncology Inc.?

Dennis M. Lanfear is Coherus Oncology Inc.'s President & CEO.

How many directors are on Coherus Oncology Inc.'s board?

Coherus Oncology Inc.'s board has 11 directors: Ali J. Satvat, Charles W. Newton, Dennis M. Lanfear, Georgia Erbez, Jill O'Donnell-Tormey, Kimberly Jo Tzoumakas, Lee Nisley Newcomer, Mark Stolper, Mats Wahlstrom, Michael Lee Ryan and 1 other.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="coherus-oncology-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.